EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial

Claire Emson, Joseph K Han, Claire Hopkins, Sara Asimus iD, Jennifer A Cann, David Chain, Yuling Wu, Yasa Reddy, Christopher McCrae, David Cohen, James L Kreindler, Viktoria Werkström und 3 weitere

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16087 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Claire Emson und 14 weiteren Autor:innen. Beteiligte Einrichtung: AstraZeneca, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Nasal Polyps, Antibodies, Monoclonal, Humanized, Sinusitis, Rhinitis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Benralizumab, a humanized, afucosylated monoclonal antibody against the interleukin 5 receptor, α subunit, causes rapid depletion of eosinophils by antibody‐dependent cellular cytotoxicity. We investigated the pharmacokinetic and pharmacodynamic effects of benralizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) from the phase III OSTRO trial.

Methods

Patients received a placebo or 30 mg of benralizumab by subcutaneous injection every 8 weeks (first three doses every 4 weeks) to week 48; a subset of patients continued in an extended follow‐up period to assess treatment durability to week 80. Serum benralizumab concentrations and blood eosinophil and basophil counts were assessed to week 80. Biomarker assessments were performed on nasal polyp tissue biopsies at week 56 and nasal lining fluid at weeks 24 and 56 to examine changes in immune cells and inflammatory mediators.

Results

Among 185 patients in this analysis, 93 received benralizumab. Serum benralizumab concentrations reached a steady state by week 24 (median concentration 385.52 ng mL −1 ); blood eosinophils were almost fully depleted and blood basophils were reduced between weeks 16 and 56. Nasal polyp tissue eosinophils decreased with benralizumab from 57.6 cells mm −2 at baseline to 0 cells mm −2 at week 56 ( P < .001 vs placebo), and tissue mast cells were numerically reduced. In nasal lining fluid, eosinophil‐derived neurotoxin was significantly reduced at weeks 24 and 56 ( P < .001) and interleukin‐17 at week 56 ( P < .05) with benralizumab.

Conclusion

Benralizumab treatment led to rapid, sustained, nearly complete depletion of eosinophils from blood and nasal polyp tissue in patients with CRSwNP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal PolypsAntibodies, Monoclonal, HumanizedSinusitisRhinitisEosinophilsHumansMaleChronic DiseaseFemaleMiddle AgedAdultDouble-Blind MethodBasophilsAgedLeukocyte CountInjections, SubcutaneousTreatment OutcomeRhinosinusitis

Stichwörter der Autor:innen

basophilsbenralizumabchronic rhinosinusitis with nasal polypseosinophilsinterleukin‐5

Substanzen

Antibodies, Monoclonal, Humanizedbenralizumab

Autor:innen und Institutionen

  • AstraZeneca, Gaithersburg, Maryland, USA.
  • Eastern Virginia Medical School, Norfolk, Virginia, USA.
  • Guy's and St. Thomas' NHS Trust, London, UK.
  • AstraZeneca, Gothenburg, Sweden.
  • Department of Medical Affairs, Vertex Pharmaceuticals, Boston, Massachusetts, USA.
  • Department of Otorhinolaryngology, University Hospital Düsseldorf, Düsseldorf, Germany.

ORCID-Profile: Sara Asimus

Förderung

  • AstraZeneca

Zitieren

APA

Emson, C., Han, J. K., Hopkins, C., Asimus, S., Cann, J. A., Chain, D., Wu, Y., Reddy, Y., McCrae, C., Cohen, D., Kreindler, J. L., Werkström, V., Jison, M., Wagenmann, M., & Bachert, C. (2024). Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16087

Vancouver

Emson C, Han JK, Hopkins C, Asimus S, Cann JA, Chain D, et al. Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16087

BibTeX
@article{Emson2024,
  author = {Emson, Claire and Han, Joseph K and Hopkins, Claire and Asimus, Sara and Cann, Jennifer A and Chain, David and Wu, Yuling and Reddy, Yasa and McCrae, Christopher and Cohen, David and Kreindler, James L and Werkström, Viktoria and Jison, Maria and Wagenmann, Martin and Bachert, Claus},
  title = {Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo‐controlled OSTRO trial},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16087}
}
Kostenlos starten →